{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of events to estimate upper bound","groupId":"OG000","lowerLimit":"13.2","upperLimit":"NA","value":"26.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Duration of response from start of first objective tumor response (CR or PR) by independent review group to disease progression or death due to any cause in participants with CR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion","id":"OG000","title":"Brentuximab Vedotin"}],"paramType":"MEDIAN","populationDescription":"Participants with complete remission among the intention to treat population","reportingStatus":"POSTED","timeFrame":"up to approximately 3 years","title":"Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis","type":"SECONDARY","unitOfMeasure":"months"}